- Home
- FLC vs BDSX Comparison
FLC vs BDSX Comparison
Compare FLC & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- BDSX
- Stock Information
- Founded
- FLC 2003
- BDSX 2005
- Country
- FLC United States
- BDSX United States
- Employees
- FLC N/A
- BDSX N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- BDSX Precision Instruments
- Sector
- FLC Finance
- BDSX Health Care
- Exchange
- FLC Nasdaq
- BDSX Nasdaq
- Market Cap
- FLC 176.2M
- BDSX 215.3M
- IPO Year
- FLC N/A
- BDSX 2020
- Fundamental
- Price
- FLC $16.85
- BDSX $1.15
- Analyst Decision
- FLC
- BDSX Strong Buy
- Analyst Count
- FLC 0
- BDSX 4
- Target Price
- FLC N/A
- BDSX $3.08
- AVG Volume (30 Days)
- FLC 37.8K
- BDSX 311.6K
- Earning Date
- FLC 01-01-0001
- BDSX 02-28-2025
- Dividend Yield
- FLC 6.64%
- BDSX N/A
- EPS Growth
- FLC N/A
- BDSX N/A
- EPS
- FLC N/A
- BDSX N/A
- Revenue
- FLC N/A
- BDSX $65,562,000.00
- Revenue This Year
- FLC N/A
- BDSX $46.97
- Revenue Next Year
- FLC N/A
- BDSX $31.44
- P/E Ratio
- FLC N/A
- BDSX N/A
- Revenue Growth
- FLC N/A
- BDSX 48.92
- 52 Week Low
- FLC $12.62
- BDSX $1.09
- 52 Week High
- FLC $15.45
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- FLC 55.43
- BDSX 34.26
- Support Level
- FLC $16.46
- BDSX $1.09
- Resistance Level
- FLC $16.89
- BDSX $1.51
- Average True Range (ATR)
- FLC 0.23
- BDSX 0.10
- MACD
- FLC 0.02
- BDSX -0.04
- Stochastic Oscillator
- FLC 74.58
- BDSX 12.77
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.